Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bytes Technology H1 trading 'substantially in line' with expectations

(Sharecast News) - Software and security firm Bytes Technology said on Thursday that it had delivered "a resilient performance" in the six months ended 31 August, with trading "substantially in line" with expectations. Gross invoiced income was expected to be roughly £1.33bn, while gross profits were seen at no less than £82m, and operating profits were pegged to be at least £33m.

Bytes' net cash position at the end of the first half was approximately £82m, after paying £41m of final and special dividends and purchasing £1m shares in the period as part of its £25m repurchase programme. Cash conversion in H1 was said to reflect Bytes' normal weighting to the second half, with strong cash conversion expected for the full year.

The FTSE 250-listed group also cautioned that although it had "a strong pipeline" going into the second half, it remained mindful that comparatives would be impacted by "the particularly strong trading performance" it experienced in the last few months of the prior financial year.

Chief executive Sam Mudd said: "We delivered a resilient performance, improving through the period as we successfully settled into our new corporate sales structure, and I am grateful to our teams for their ongoing efforts.

"We remain confident in our growth strategy and believe we are well-positioned to benefit from the structural demand drivers we see in our markets, including cloud computing, cyber security and AI."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.